Proton Pump Inhibitors in Pediatrics: Evaluation of Efficacy in GERD Therapy
| Autor: | Andrea Chiaro, Italia Loddo, D. Comito, Valeria Ferraù, Claudio Romano |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Pediatrics
medicine.medical_specialty Lansoprazole Esomeprazole law.invention Gastric Acid Randomized controlled trial law Proton Pump Inhibitors Children Animals Humans Medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Esophagus Child Omeprazole business.industry fungi Age Factors Infant General Medicine medicine.disease digestive system diseases Chronic cough medicine.anatomical_structure Child Preschool Regurgitation (digestion) Gastroesophageal Reflux GERD medicine.symptom business medicine.drug |
| Zdroj: | Current Clinical Pharmacology. 6:41-47 |
| ISSN: | 1574-8847 |
| DOI: | 10.2174/157488411794941296 |
| Popis: | Gastroesophageal reflux (GER) is defined as the passage of gastric contents into the esophagus. It occurs in healthy infants and can be considered physiological process. Uncomplicated GER can present with recurrent vomiting or regurgitation without any other symptoms and is usually managed by educating, reassuring, and guiding the parent without other intervention. GER disease (GERD) refers to the appearance of troublesome symptoms or complications (erosive esophagitis, ulceration, Barrett's esophagus) and may warrant acid suppression. Proton Pump Inhibitors (PPIs) are the most effective pharmacologic agents available for the treatment of children with GERD. In the pediatric practice only omeprazole, lansoprazole and esomeprazole are available over the first year of life. The empiric use in infants with nonspecific symptoms (excessive crying, regurgitation, feeding refusal, chronic cough) is frequent without randomized controlled study. Our paper will focus on the correct indications, dosages, duration of treatment and safety of PPI use in pediatric population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|